製品番号: HY-A0096

Iloprost

(別名: Ciloprost; ZK 36374)

5 Cited Publications

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.32%
CAS 番号: 78919-13-8
分子式: C₂₂H₃₂O₄
分子量:360.49

保管条件:

Pure form -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year

Iloprost 構造式

CAS 番号: 78919-13-8

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (5)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

Prostaglandin Receptor アイソフォーム固有の製品をすべて表示 :

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	1 x 10^-8 M Compound: Iloprost	Displacement of [3H]iloprost from human recombinant Prostanoid IP receptor expressed in HEK293 cells Displacement of [3H]iloprost from human recombinant Prostanoid IP receptor expressed in HEK293 cells	[PMID: 26988801]
HEK293	IC₅₀	1 x 10^-8 M Compound: Iloprost	Displacement of [3H]iloprost from human recombinant IP receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method Displacement of [3H]iloprost from human recombinant IP receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method	[PMID: 27876250]
HEK293	IC₅₀	1 x 10^-2 μM Compound: Iloprost	Displacement of [3H]iloprost from human recombinant IP receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method Displacement of [3H]iloprost from human recombinant IP receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method	[PMID: 27876250]

体外実験

Prostacyclin (PGI2) is synthesised in oviductal fluid and enhance the embryo development^[1].
Iloprost is an PGI2 analog, and affects maturation and developmental competence of bovine oocytes^[1].
Iloprost (0.5 μM; 22-24 h) increases blastocyst rates of bovine embryos as well as proportion of expanded blastocysts^[1].
Iloprost (0.5 μM; 22-24 h) assists maturation rates and cumulus cell expansion of bovine oocytes, and increases the mRNA expression of genes related to cumulus expansion^[1].
Iloprost (0.5 μM; 22-24 h) reduces the occurrence of apoptosis in COCs and promotes an anti-apoptotic balance in the transcription of genes involved in apoptosis (BAX and BCL2) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

Bovine oocytes: cumulus oocyte complexes (COCs)
Concentration:

0.5 μM
Incubation Time:

22-24 hours
Result:

Increased mRNA expression levels of cysteine proteinases cathepsins, including ADAM17, AREG, and TNFAIP6 23 and cathepsin genes (CTSK and CTSS).

体内実験

Iloprost (0.3 mg/kg/min; via s.c. mini pumps; 33 d) has a significant anti-metastatic activity in a spontaneously metastasizing tumor model in rat^[2].
Iloprost (0.2 mg/kg/d; i.p.; 10 d) attenuates hyperoxia effects and reduces inflammation in the newborn mouse lung, with Cyclooxygenase-2 (COX-2/PTGS2) mediates hyperoxia-induced impairment^[3].
Iloprost (0.2 mg/kg; i.v. or i.p.) exhibits short half-life, and is often administered by means of frequent (every 2-4h) inhalation in treatment^[4].
Comparison of pharmacokinetic parameter in rats and mice^[4]

Animal	Route	Dose (mg/kg)	AUC (ng•h/mL)	F (%)	CL (range) (mL/min/kg)	t_1/2λi (min)	t_1/2λz (min)
Mice	i.v.	0.2	21.9	100	152	3	15
Rat	i.g.	0.2	2.2	10	/	4	58

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Spontaneously metastasizing R 3327 MAT Lu prostate carcinoma in Cop rat^[2]
Dosage:

0.3 mg/kg/min
Administration:

Subcutaneous administration via Alzet mini pumps; continuously for 33 days
Result:

Reduced the number of visible lung metastases, but had no effect on the growth of the primary tumor.
This action was based on the ability to reduce the attachment of tumor cells to platelets and to inhibit adhesion of tumor cells-platelet aggregates to the endothelial lining.

Animal Model:

Newborn C57BL/6 mice (4-day-old)^[3]
Dosage:

0.2 mg/kg
Administration:

Intraperitoneal injection; once daily; 10 days
Result:

Reduced markedly pro-inflammatory cytokines IL-1β and TNF-α mRNA and protein.
Inhibited alveolar septation, reduced hyperoxia-induced total lung resistance and myeloperoxidase, prevented hyperoxia-reduced lung microvascular density.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 78919-13-8
性状 Oil
分子量 360.49
分子式 C₂₂H₃₂O₄
Color Colorless to light yellow
SMILES

O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)C(C)CC#CC)[C@@]2([H])C\1
別名

Ciloprost; ZK 36374
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Pure form	-20°C	3 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All Histological Imaging/StainingIFWBRT-PCR

Sort by:

Journal Impact Factor

Cell Mol Life Sci

Prostaglandin I2 signaling prevents angiotensin II-induced atrial remodeling and vulnerability to atrial fibrillation in mice. [Abstract]

2024 Jun 15;81(1):264. PMID: 38878214

Iloprost purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Jun 15;81(1):264. [Abstract]

Representative Sirus red staining of left atrial tissues of Saline/Vehicle, Saline/Iloprost (0.2 mg/kg, i.p.), Ang II/Vehicle, and Ang II/Iloprost mice.

Iloprost purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Jun 15;81(1):264. [Abstract]

Immunofluorescence staining of α-SMA (alpha-smooth muscle actin) and Vimentin. in left atrial tissues treated with Iloprost (0.2 mg/kg, i.p.).

Iloprost purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Jun 15;81(1):264. [Abstract]

Western blot analysis of Collagen I, α-SMA and Periostin protein levels in the atrial tissues treated with Iloprost (0.2 mg/kg, i.p.).

Iloprost purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2024 Jun 15;81(1):264. [Abstract]

Mouse primary atrial fibroblasts were starved for 24 h and then treated with Ang II (1 µM) and/or iloprost (10 µM). Quantification of Col1a1 (collagen type I alpha 1 chain) and Acta2 (actin alpha 2) mRNA levels at 8 h.
Cells

Blastocyst-Derived Lactic Acid May Regulate S100A6 Expression and Function in Mouse Decidualization via Stimulation of Uterine Epithelial Arachidonic Acid Secretion. [Abstract]

2024 Jan 23;13(3):206. PMID: 38334598
Eur J Pharmacol

Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment. [Abstract]

2024 Jan 5:962:176199. PMID: 38029870
J Cell Mol Med

Iloprost Concentration-Dependently Attenuates Platelet Function and Apoptosis by Elevating PKA Activity. [Abstract]

2025 Feb;29(3):e70403. PMID: 39929746
J Dent Sci

The additive effect of iloprost on the biological properties of Mineral trioxide aggregate on mesenchymal stem cells. [Abstract]

2022 Jan;17(1):225-232. PMID: 35028042

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (277.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7740 mL

13.8700 mL

27.7400 mL

5 mM

0.5548 mL

2.7740 mL

5.5480 mL

10 mM

0.2774 mL

1.3870 mL

2.7740 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kowalczyk-Zieba I, et al. Iloprost affects in vitro maturation and developmental competence of bovine oocytes. Theriogenology. 2020 Nov;157:286-296. [Content Brief]

[2]. Hildebrand M. Pharmacokinetics of iloprost and cicaprost in mice. Prostaglandins. 1992 Nov;44(5):431-42. [Content Brief]

[3]. Olave N, et al. Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice. Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L535-L544. [Content Brief]

[4]. Schneider MR, et al. Effects of prostacyclin analogues in in vivo tumor models. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:901-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7740 mL	13.8700 mL	27.7400 mL	69.3501 mL
	5 mM	0.5548 mL	2.7740 mL	5.5480 mL	13.8700 mL
	10 mM	0.2774 mL	1.3870 mL	2.7740 mL	6.9350 mL
	15 mM	0.1849 mL	0.9247 mL	1.8493 mL	4.6233 mL
	20 mM	0.1387 mL	0.6935 mL	1.3870 mL	3.4675 mL
	25 mM	0.1110 mL	0.5548 mL	1.1096 mL	2.7740 mL
	30 mM	0.0925 mL	0.4623 mL	0.9247 mL	2.3117 mL
	40 mM	0.0694 mL	0.3468 mL	0.6935 mL	1.7338 mL
	50 mM	0.0555 mL	0.2774 mL	0.5548 mL	1.3870 mL
	60 mM	0.0462 mL	0.2312 mL	0.4623 mL	1.1558 mL
	80 mM	0.0347 mL	0.1734 mL	0.3468 mL	0.8669 mL
	100 mM	0.0277 mL	0.1387 mL	0.2774 mL	0.6935 mL

Iloprost

5 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Iloprost

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Fatty Acids Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Alkyne Compound Library

MedChemExpress（MCE）の使用を引用している文献 Iloprost

Prostaglandin Receptor アイソフォーム固有の製品をすべて表示

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (5)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Iloprost 関連分類

HY-A0096 関連分類